Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India

Studies have shown better graft function and reduced acute rejection rates among renal transplant recipients who were on Tacrolimus (Tac)-based immunosuppression regimens as compared to cyclosporine (CsA)-based regimens in the first year. However, the long-term follow-up data did not reveal better o...

Full description

Bibliographic Details
Main Authors: Kiran Chandra Patro, S Ramakrishnan, Santhosh Kumar, J Roopa, R Dilip
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Indian Journal of Transplantation
Subjects:
Online Access:http://www.ijtonline.in/article.asp?issn=2212-0017;year=2018;volume=12;issue=3;spage=165;epage=168;aulast=Patro
id doaj-0b50fe6903f14563ad5faaff087152b4
record_format Article
spelling doaj-0b50fe6903f14563ad5faaff087152b42020-11-25T01:52:49ZengWolters Kluwer Medknow PublicationsIndian Journal of Transplantation2212-00172212-00252018-01-0112316516810.4103/ijot.ijot_6_18Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South IndiaKiran Chandra PatroS RamakrishnanSanthosh KumarJ RoopaR DilipStudies have shown better graft function and reduced acute rejection rates among renal transplant recipients who were on Tacrolimus (Tac)-based immunosuppression regimens as compared to cyclosporine (CsA)-based regimens in the first year. However, the long-term follow-up data did not reveal better outcomes in the Tac-based regimens. In view of the short term benefits, the trend has been to change to Tac-based regimens off late. Data from the Indian subcontinent are, however, sparse. We, therefore, looked at our data to ascertain if Tac-based regimen does have better outcomes in our population. We studied a total of 108 individuals who underwent renal transplantation between January 2007 and June 2013, with a mean follow-up of 38.22 months (comparable to both groups). In our group, males constituted 77.8%,; and among the 108 individuals, 16.7% were diabetics. New-onset diabetes after renal transplantation was more common in the Tac group (21 vs. 12 and was statistically significant [P = 0.03]). At the last follow-up, serum creatinine was higher in the CsA group (1.77 mg/dl vs. 1.35 mg/dl) and was statistically significant (P = 0.03). Individuals requiring hemodialysis were also significantly higher in the CsA group (9 vs. 2; P = 0.05). The patient survival was similar in both groups (1-year and 5-year follow-up); however, graft survival was better in Tac group as compared to CsA group (0.94 vs. 0.88 at 1 year and 0.85 vs. 0.72 at 5 years).http://www.ijtonline.in/article.asp?issn=2212-0017;year=2018;volume=12;issue=3;spage=165;epage=168;aulast=PatroComparisoncyclosporinerenal transplant recipientsrenal transplantationtacrolimus
collection DOAJ
language English
format Article
sources DOAJ
author Kiran Chandra Patro
S Ramakrishnan
Santhosh Kumar
J Roopa
R Dilip
spellingShingle Kiran Chandra Patro
S Ramakrishnan
Santhosh Kumar
J Roopa
R Dilip
Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
Indian Journal of Transplantation
Comparison
cyclosporine
renal transplant recipients
renal transplantation
tacrolimus
author_facet Kiran Chandra Patro
S Ramakrishnan
Santhosh Kumar
J Roopa
R Dilip
author_sort Kiran Chandra Patro
title Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
title_short Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
title_full Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
title_fullStr Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
title_full_unstemmed Comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – Single-center experience from South India
title_sort comparison of patient and graft survival in tacrolimus versus cyclosporine-based immunosuppressive regimes in renal transplant recipients – single-center experience from south india
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Transplantation
issn 2212-0017
2212-0025
publishDate 2018-01-01
description Studies have shown better graft function and reduced acute rejection rates among renal transplant recipients who were on Tacrolimus (Tac)-based immunosuppression regimens as compared to cyclosporine (CsA)-based regimens in the first year. However, the long-term follow-up data did not reveal better outcomes in the Tac-based regimens. In view of the short term benefits, the trend has been to change to Tac-based regimens off late. Data from the Indian subcontinent are, however, sparse. We, therefore, looked at our data to ascertain if Tac-based regimen does have better outcomes in our population. We studied a total of 108 individuals who underwent renal transplantation between January 2007 and June 2013, with a mean follow-up of 38.22 months (comparable to both groups). In our group, males constituted 77.8%,; and among the 108 individuals, 16.7% were diabetics. New-onset diabetes after renal transplantation was more common in the Tac group (21 vs. 12 and was statistically significant [P = 0.03]). At the last follow-up, serum creatinine was higher in the CsA group (1.77 mg/dl vs. 1.35 mg/dl) and was statistically significant (P = 0.03). Individuals requiring hemodialysis were also significantly higher in the CsA group (9 vs. 2; P = 0.05). The patient survival was similar in both groups (1-year and 5-year follow-up); however, graft survival was better in Tac group as compared to CsA group (0.94 vs. 0.88 at 1 year and 0.85 vs. 0.72 at 5 years).
topic Comparison
cyclosporine
renal transplant recipients
renal transplantation
tacrolimus
url http://www.ijtonline.in/article.asp?issn=2212-0017;year=2018;volume=12;issue=3;spage=165;epage=168;aulast=Patro
work_keys_str_mv AT kiranchandrapatro comparisonofpatientandgraftsurvivalintacrolimusversuscyclosporinebasedimmunosuppressiveregimesinrenaltransplantrecipientssinglecenterexperiencefromsouthindia
AT sramakrishnan comparisonofpatientandgraftsurvivalintacrolimusversuscyclosporinebasedimmunosuppressiveregimesinrenaltransplantrecipientssinglecenterexperiencefromsouthindia
AT santhoshkumar comparisonofpatientandgraftsurvivalintacrolimusversuscyclosporinebasedimmunosuppressiveregimesinrenaltransplantrecipientssinglecenterexperiencefromsouthindia
AT jroopa comparisonofpatientandgraftsurvivalintacrolimusversuscyclosporinebasedimmunosuppressiveregimesinrenaltransplantrecipientssinglecenterexperiencefromsouthindia
AT rdilip comparisonofpatientandgraftsurvivalintacrolimusversuscyclosporinebasedimmunosuppressiveregimesinrenaltransplantrecipientssinglecenterexperiencefromsouthindia
_version_ 1724992809809739776